NeuroOne Medical Technologies Corporation (NMTC)
Market Cap | 28.34M |
Revenue (ttm) | 5.75M |
Net Income (ttm) | -7.19M |
Shares Out | 30.86M |
EPS (ttm) | -0.25 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 29,609 |
Open | 0.910 |
Previous Close | 0.935 |
Day's Range | 0.909 - 0.970 |
52-Week Range | 0.551 - 1.390 |
Beta | 0.65 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 13, 2025 |
About NMTC
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, radio frequency and brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company also foc... [Read more]
Financial Performance
In 2024, NMTC's revenue was $3.45 million, an increase of 1.33% compared to the previous year's $3.41 million. Losses were -$12.32 million, 3.87% more than in 2023.
Financial StatementsNews

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update
EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgic...

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace
EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgic...

NeuroOne CEO Joins Today's Marketplace To Discuss The Latest Treatments for Epilepsy
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) CEO Dave Rosa and Jessic...

NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Submission for New Intended Use That Leverages Company's Patented OneRF® Technology Platform Expected in May 2025 EDEN PRAIRIE, Minn., March 11, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies...

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgic...

NeuroOne Medical Technologies Corporation (NMTC) Q1 2025 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Dave Rosa - CEO Ron McClurg - CFO Chris Volker - COO Operato...

NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update
Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOB...

NeuroOne® to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8:30 a.m. Eastern Time
EDEN PRAIRIE, Minn., Feb. 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...

NeuroOne® Regains Compliance with Nasdaq Listing Requirements
EDEN PRAIRIE, Minn., Feb. 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...

NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million
First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue

Stock Picks From Seeking Alpha's December 2024 New Analysts
In December, we welcomed 29 new analysts to Seeking Alpha and in this article we are showcasing their stock picks and investment strategies. Five buy picks are highlighted on Viasat, Newmont, NeuroOne...

NeuroOne® Announces Virtual Investor Webinar on January 9, 2025 at 11:00 a.m. EST
Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Na...

NeuroOne Medical Technologies Corporation (NMTC) Q4 2024 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q4 2024 Earnings Conference Call December 17, 2024 9:00 AM ET Company Participants Dave Rosa - Chief Executive Officer Ron McClurg - Chief Fina...

NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025
Company's Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly

NeuroOne Medical Technologies: A Small-Cap Electrode Technology Play With Multiple Catalysts Ahead
NeuroOne is a commercial stage medical device company with FDA-cleared electrodes used in prominent U.S. medical centers for epilepsy diagnosis and treatment. NMTC is partnered with Zimmer Biomet, a $...

NeuroOne Medical Technologies Corporation to Present at November 21st Virtual Investor Summit Microcap Event
EDEN PRAIRIE, MN / ACCESSWIRE / November 13, 2024 / NeuroOne Medical Technologies Corporation (Nasdaq:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical ca...

NeuroOne® Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System
License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS MarketsAgreement expected to boost NeuroOne sales revenue and profitability

NeuroOne® Spinal Cord Stimulation Electrode Technology to be Featured at The Business of Pain Conference
EDEN PRAIRIE, Minn., Sept. 24, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgic...

NeuroOne® Announces Breakthrough Case Completed with OneRF™ Ablation System at the University Hospitals in Cleveland
Forty-four ablations performed successfully in one patient Patient currently reportedly seizure free with improvements in mood and memory EDEN PRAIRIE, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- NeuroO...

NeuroOne® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
EDEN PRAIRIE, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgic...

NeuroOne Medical Technologies Corporation (NMTC) Q3 2024 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q3 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Dave Rosa - Chief Executive Officer Ron McClurg - Chief Financ...

NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgica...

NeuroOne® to Report Third Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on August 14
EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...

NeuroOne® Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation
ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024

NeuroOne Medical Technologies Corporation (NMTC) Q2 2024 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q2 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Dave Rosa - President & Chief Executive Officer Ron McClurg - Chi...